新型酮内酯类药物ABT-773对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧和厌氧病原体的体外活性。
In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
作者信息
Goldstein E J, Conrads G, Citron D M, Merriam C V, Warren Y, Tyrrell K
机构信息
R. M. Alden Research Laboratory Santa Monica-UCLA Medical Center, Santa Monica, California 90404, USA.
出版信息
Antimicrob Agents Chemother. 2001 Aug;45(8):2363-7. doi: 10.1128/AAC.45.8.2363-2367.2001.
Abstract
The comparative in vitro activities of ABT-773 against 207 aerobic and 162 anaerobic antral sinus puncture isolates showed that erythromycin-resistant pneumococcal strains were susceptible to ABT-773 (< or =0.125 microg/ml); the MIC at which 90% of the isolates tested were inhibited for Haemophilus influenzae and other Haemophilus spp. was 4 microg/ml; and all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by < or =0.125 microg/ml. Among the anaerobes tested, only fusobacteria (45%) required > or =4 microg of ABT-773/ml for inhibition. ABT-773 may offer a therapeutic alternative for sinus infections.
摘要
ABT - 773对207株需氧菌和162株厌氧性鼻窦穿刺分离菌的体外比较活性研究表明，对红霉素耐药的肺炎球菌菌株对ABT - 773敏感（≤0.125微克/毫升）；90%受试流感嗜血杆菌及其他嗜血杆菌属菌株被抑制时的最低抑菌浓度（MIC）为4微克/毫升；所有莫拉克斯氏菌属及产β - 内酰胺酶的普雷沃氏菌属菌株均被≤0.125微克/毫升的ABT - 773所抑制。在受试厌氧菌中，只有梭杆菌（45%）被抑制时所需的ABT - 773浓度≥4微克/毫升。ABT - 773可能为鼻窦感染提供一种治疗选择。
相似文献
1
In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.新型酮内酯类药物ABT-773对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧和厌氧病原体的体外活性。
Antimicrob Agents Chemother. 2001 Aug;45(8):2363-7. doi: 10.1128/AAC.45.8.2363-2367.2001.
2
In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis.替利霉素及10种口服药物对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧和厌氧病原体的体外活性。
Antimicrob Agents Chemother. 2003 Jun;47(6):1963-7. doi: 10.1128/AAC.47.6.1963-1967.2003.
3
Comparative in vitro activities of ABT-773 against aerobic and anaerobic pathogens isolated from skin and soft-tissue animal and human bite wound infections.ABT-773对从皮肤及软组织动物和人类咬伤伤口感染中分离出的需氧和厌氧病原体的体外比较活性。
Antimicrob Agents Chemother. 2000 Sep;44(9):2525-9. doi: 10.1128/AAC.44.9.2525-2529.2000.
4
In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
Diagn Microbiol Infect Dis. 2002 Feb;42(2):113-8. doi: 10.1016/s0732-8893(01)00341-8.
5
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.新型氟喹诺酮类药物ABT-492对从鼻窦炎患者上颌窦穿刺标本中分离出的155种需氧菌和171种厌氧菌的体外活性。
Antimicrob Agents Chemother. 2003 Sep;47(9):3008-11. doi: 10.1128/AAC.47.9.3008-3011.2003.
6
Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis.阿莫西林-克拉维酸对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧菌和厌氧菌的体外比较活性。
Antimicrob Agents Chemother. 1999 Mar;43(3):705-7. doi: 10.1128/AAC.43.3.705.
7
Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.ABT-773对362株厌氧菌临床分离株的体外活性比较
Antimicrob Agents Chemother. 2001 Jan;45(1):345-8. doi: 10.1128/AAC.45.1.345-348.2001.
8
Bacteriological findings and antimicrobial resistance in odontogenic and non-odontogenic chronic maxillary sinusitis.牙源性和非牙源性慢性上颌窦炎的细菌学发现和抗菌药物耐药性。
J Med Microbiol. 2011 Sep;60(Pt 9):1353-1359. doi: 10.1099/jmm.0.031476-0. Epub 2011 Apr 15.
9
Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.与流感嗜血杆菌和卡他莫拉菌对其他11种药物的敏感性相比，它们对ABT-773的敏感性。
Antimicrob Agents Chemother. 2001 Jan;45(1):67-72. doi: 10.1128/AAC.45.1.67-72.2001.
10
In vitro activity of the ketolide ABT-773.酮内酯ABT-773的体外活性
Antimicrob Agents Chemother. 2001 Oct;45(10):2922-4. doi: 10.1128/AAC.45.10.2922-2924.2001.
引用本文的文献
1
Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.西他霉素与克拉霉素治疗社区获得性肺炎的比较：来自两项双盲、随机、平行分组、多中心、跨国非劣效性研究的疗效和安全性结果。
Antimicrob Agents Chemother. 2012 Apr;56(4):2037-47. doi: 10.1128/AAC.05596-11. Epub 2012 Jan 30.
2
Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.塞曲霉素的稳态血浆及肺内药代动力学与药效学
Antimicrob Agents Chemother. 2004 Sep;48(9):3508-15. doi: 10.1128/AAC.48.9.3508-3515.2004.
3
The ketolides: a critical review.酮内酯类药物：综述
Drugs. 2002;62(12):1771-804. doi: 10.2165/00003495-200262120-00006.
本文引用的文献
1
Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin.检测方法的差异对流感嗜血杆菌对氨苄西林、阿奇霉素、克拉霉素和泰利霉素敏感性的影响。
J Clin Microbiol. 2001 Jan;39(1):43-6. doi: 10.1128/JCM.39.1.43-46.2001.
2
Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.ABT-773对362株厌氧菌临床分离株的体外活性比较
Antimicrob Agents Chemother. 2001 Jan;45(1):345-8. doi: 10.1128/AAC.45.1.345-348.2001.
3
The in vitro activity of ABT773, a new ketolide antimicrobial agent.新型酮内酯类抗菌药物ABT773的体外活性
J Antimicrob Chemother. 2000 Dec;46(6):1017-22. doi: 10.1093/jac/46.6.1017.
4
In vitro activity of ABT-773 against anaerobic bacteria.
Eur J Clin Microbiol Infect Dis. 2000 Aug;19(8):635-7. doi: 10.1007/s100960000337.
5
Comparative in vitro activities of ABT-773 against aerobic and anaerobic pathogens isolated from skin and soft-tissue animal and human bite wound infections.ABT-773对从皮肤及软组织动物和人类咬伤伤口感染中分离出的需氧和厌氧病原体的体外比较活性。
Antimicrob Agents Chemother. 2000 Sep;44(9):2525-9. doi: 10.1128/AAC.44.9.2525-2529.2000.
6
Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership.急性细菌性鼻窦炎抗菌治疗指南。鼻窦与过敏健康合作组织。
Otolaryngol Head Neck Surg. 2000 Jul;123(1 Pt 2):5-31.
7
In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.新型酮内酯类药物ABT-773对近期临床分离的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的体外活性。
Antimicrob Agents Chemother. 2000 Feb;44(2):447-9. doi: 10.1128/AAC.44.2.447-449.2000.
8
Resistance to antimicrobials used for therapy of otitis media and sinusitis: effect of previous antimicrobial therapy and smoking.中耳炎和鼻窦炎治疗中对抗菌药物的耐药性：既往抗菌治疗及吸烟的影响
Ann Otol Rhinol Laryngol. 1999 Jul;108(7 Pt 1):645-7. doi: 10.1177/000348949910800704.
9
Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis.阿莫西林-克拉维酸对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧菌和厌氧菌的体外比较活性。
Antimicrob Agents Chemother. 1999 Mar;43(3):705-7. doi: 10.1128/AAC.43.3.705.
10
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.1996 - 1997年呼吸道疾病流行季节美国肺炎链球菌、流感嗜血杆菌和卡他莫拉菌耐药性监测。实验室研究小组。
Diagn Microbiol Infect Dis. 1997 Dec;29(4):249-57. doi: 10.1016/s0732-8893(97)00195-8.
Zotero 插件